No Data
No Data
The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.
According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.
The 15% Return Delivered to PKU HealthCareLtd's (SZSE:000788) Shareholders Actually Lagged YoY Earnings Growth
PKU HealthCare Corp. (000788.SZ): Currently, there are no related products for hair growth.
On December 24, Gulonghui reported that PKU HealthCare Corp. (000788.SZ) stated on the investor interaction platform that the company currently has no products related to hair growth. The company mainly engages in the research and development, production, and sales of Chemical Drug formulations as well as pharmaceutical circulation and other businesses. The company's pharmaceutical manufacturing Sector currently focuses on core areas such as anti-infection, analgesics, mental health, and chronic diseases, primarily with generic drugs.
PKU HealthCare Corp. (000788.SZ): The approval has been granted for the addition of a 10mg specification for Buprenorphine Hydrochloride Tablets.
On December 23, Gelonghui reported that PKU HealthCare Corp. (000788.SZ) announced that it recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The pharmaceutical name is Buprenorphine Hydrochloride Tablets, and the administration approved the supplementary application for an additional 10mg specification, issuing a drug approval number. This product has passed the consistency evaluation of quality and efficacy for generic pharmaceuticals.
PKU HealthCare's Drug for Schizophrenia, Bipolar Gets Nod for Registration
pku healthcare corp., (000788.SZ) has been approved as the holder of the marketing authorization for "oseltamivir phosphate granules for oral suspension"
pku healthcare corp. (000788.SZ) announced that recently, the company has received the approval and issuance from the National Medical Products Administration...
PKU HealthCare Corp.,Ltd.'s (SZSE:000788) 28% Share Price Plunge Could Signal Some Risk
No Data
